tiprankstipranks
Trending News
More News >
Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719)
:0719

Shandong Xinhua Pharmaceutical Company Limited Class H (0719) AI Stock Analysis

Compare
2 Followers

Top Page

HK

Shandong Xinhua Pharmaceutical Company Limited Class H

(0719)

Rating:70Outperform
Price Target:―
Shandong Xinhua Pharmaceutical shows a strong financial foundation with growth in revenue and stability in operational efficiency. However, technical indicators point towards weak momentum and bearish trends, creating caution for potential investors. Despite these technical challenges, the stock's valuation is compelling due to a low P/E ratio and high dividend yield, providing a buffer for income-focused investors. Improving cash flow could enhance future growth potential.

Shandong Xinhua Pharmaceutical Company Limited Class H (0719) vs. iShares MSCI Hong Kong ETF (EWH)

Shandong Xinhua Pharmaceutical Company Limited Class H Business Overview & Revenue Model

Company DescriptionShandong Xinhua Pharmaceutical Company Limited Class H (0719) is a leading pharmaceutical company based in China, specializing in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. The company operates in various sectors, including active pharmaceutical ingredients (APIs), finished dosage forms, and over-the-counter (OTC) products. It is recognized for its robust portfolio of analgesics, anti-infectives, cardiovascular drugs, and central nervous system medications. As a prominent player in the pharmaceutical industry, Shandong Xinhua Pharmaceutical is committed to delivering high-quality healthcare solutions globally.
How the Company Makes MoneyShandong Xinhua Pharmaceutical Company Limited generates revenue through multiple streams, primarily focused on the production and sale of pharmaceutical products. The company's revenue model is driven by its extensive portfolio of APIs and finished dosage forms, which are supplied to both domestic and international markets. Significant revenue is also derived from its OTC products, catering to a broad consumer base seeking accessible healthcare solutions. The company benefits from strategic partnerships and collaborations with other pharmaceutical firms, enhancing its market reach and distribution capabilities. Furthermore, Shandong Xinhua Pharmaceutical invests in research and development to innovate new products, which contribute to sustaining its competitive edge and financial growth.

Shandong Xinhua Pharmaceutical Company Limited Class H Financial Statement Overview

Summary
Shandong Xinhua Pharmaceutical demonstrates solid revenue growth and operational efficiency. The balance sheet is robust with a strong equity base and manageable debt. However, cash flow constraints, particularly low free cash flow, could limit growth opportunities or debt repayment.
Income Statement
78
Positive
Shandong Xinhua Pharmaceutical shows a consistent growth in revenue with a 4.51% increase in 2024. The gross profit margin is stable at around 24.1%, and net profit margin is healthy at approximately 5.55% for 2024. EBIT and EBITDA margins are stable, indicating good operational efficiency. However, a slight decrease in gross profit percentage suggests rising costs, which is a potential risk.
Balance Sheet
75
Positive
The company's balance sheet reflects a strong equity position with an equity ratio of approximately 55.33% in 2024. The debt-to-equity ratio is manageable at 0.27, showing conservative leverage. ROE improved to 9.42%, suggesting efficient use of equity. However, rising total liabilities could be a concern if not managed prudently.
Cash Flow
65
Positive
Operating cash flow has improved in 2024, but free cash flow remains relatively low, indicating limited liquidity for expansions or debt reductions. The operating cash flow to net income ratio is moderate, suggesting cash flow generation aligns with profitability. However, the absence of significant free cash flow growth is a concern.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
8.42B8.47B8.10B7.50B6.56B6.01B
Gross Profit
1.82B2.04B2.32B2.04B1.77B1.81B
EBIT
506.98M534.37M534.58M476.71M425.59M422.49M
EBITDA
605.22M1.11B1.09B1.01B840.20M856.79M
Net Income Common Stockholders
440.24M470.02M496.51M411.06M348.55M324.86M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.34B1.25B918.33M1.16B744.66M855.77M
Total Assets
7.04B9.02B8.29B8.27B7.33B7.09B
Total Debt
1.50B1.35B1.08B1.38B1.04B1.09B
Net Debt
163.66M107.78M166.60M225.11M299.09M231.77M
Total Liabilities
3.88B3.80B3.51B3.92B3.68B3.70B
Stockholders Equity
3.02B4.99B4.55B4.13B3.47B3.22B
Cash FlowFree Cash Flow
50.64M155.19M―513.48M9.89M140.00M
Operating Cash Flow
39.34M367.61M265.28M758.24M259.12M420.19M
Investing Cash Flow
-50.54M―――――
Financing Cash Flow
251.79M184.78M-196.11M――35.04M

Shandong Xinhua Pharmaceutical Company Limited Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6.11
Price Trends
50DMA
5.75
Positive
100DMA
5.73
Positive
200DMA
5.75
Positive
Market Momentum
MACD
0.13
Negative
RSI
68.77
Neutral
STOCH
75.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0719, the sentiment is Positive. The current price of 6.11 is above the 20-day moving average (MA) of 6.00, above the 50-day MA of 5.75, and above the 200-day MA of 5.75, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 68.77 is Neutral, neither overbought nor oversold. The STOCH value of 75.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0719.

Shandong Xinhua Pharmaceutical Company Limited Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$101.88B22.1613.20%4.42%-9.60%-27.18%
76
Outperform
$26.05B14.7610.17%3.99%-8.91%-34.40%
72
Outperform
$964.10B6.55
6.13%11.71%37.04%
70
Outperform
HK$9.37B8.808.89%4.93%4.91%-11.80%
66
Neutral
$81.38B42.886.14%1.32%7.63%-24.23%
65
Neutral
$67.02B14.716.22%1.96%-2.82%11.93%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.31
1.15
22.29%
HK:2318
Ping An Insurance Company of China
47.20
12.08
34.41%
HK:1177
Sino Biopharmaceutical
4.74
2.05
75.95%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
17.38
4.03
30.22%
HK:1093
CSPC Pharmaceutical Group
8.82
2.19
32.99%
HK:0867
China Medical System Holdings
11.34
4.54
66.86%

Shandong Xinhua Pharmaceutical Company Limited Class H Corporate Events

Shandong Xinhua Pharmaceutical Reports Q1 2025 Financial Results
Apr 28, 2025

Shandong Xinhua Pharmaceutical Company Limited has released its unaudited financial results for the first quarter of 2025, showing a slight decrease in operating income by 1.81% compared to the same period last year. The company reported a significant decline in net profit attributable to shareholders, down by 20.99%, and a substantial drop in net cash flow from operating activities by 77.87%. Despite these challenges, the company’s total assets increased by 2.77%, and net assets attributable to shareholders rose by 3.28%, indicating a stable asset base.

Shandong Xinhua Pharmaceutical’s Aspirin Tablets Gain Approval
Apr 28, 2025

Shandong Xinhua Pharmaceutical Company Limited announced that its Aspirin Enteric-coated Tablets have passed the Generics Drugs Consistency Evaluation, receiving approval from the National Medical Products Administration. This approval signifies a positive step for the company, enhancing its product offerings and potentially strengthening its position in the pharmaceutical market.

Xinhua Pharmaceutical Gains Approval for Marketing License Change
Apr 28, 2025

Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for a change in the marketing license holder of its Epalrestat tablets. This approval is part of a broader agreement with Beijing Minkang Baicao Pharmaceutical Technology Company Limited, which involves the transfer of production technology and marketing authorization holder status for Mecobalamin tablets to Xinhua Pharmaceutical. This strategic move is expected to enhance Xinhua Pharmaceutical’s market position and operational capabilities in the pharmaceutical industry.

Shandong Xinhua Pharmaceutical Secures Approval for Pregabalin Oral Solution
Apr 23, 2025

Shandong Xinhua Pharmaceutical Company Limited has announced that it has received a Drug Registration Certificate for its Pregabalin oral solution from the National Medical Products Administration. This approval marks a significant step for the company, allowing it to produce and market the drug, which is used in the treatment of postherpetic neuralgia, fibromyalgia, and partial seizures, thereby potentially enhancing its market position and expanding its product offerings.

Shandong Xinhua Pharmaceutical Secures Drug Registration for Memantine Solution
Apr 23, 2025

Shandong Xinhua Pharmaceutical Company Limited has announced the receipt of the Drug Registration Certificate for its Memantine hydrochloride oral solution from the National Medical Products Administration. This approval marks a significant milestone for the company, enabling it to proceed with the production and sale of the drug, potentially enhancing its market position in the pharmaceutical industry.

Shandong Xinhua Pharmaceutical Schedules Board Meeting to Review Q1 2025 Results
Apr 14, 2025

Shandong Xinhua Pharmaceutical Company Limited has announced a board meeting scheduled for April 28, 2025, to consider and approve the unaudited results for the first quarter of 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder confidence.

Shandong Xinhua’s Aminophylline Tablets Pass Key Quality Evaluation
Apr 14, 2025

Shandong Xinhua Pharmaceutical Company Limited announced that its Aminophylline Tablets have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, as approved by the National Medical Products Administration. This approval is a significant milestone for the company, potentially enhancing its market position by ensuring the quality and efficacy of its generic drugs, which could lead to increased trust and demand from healthcare providers and patients.

Shandong Xinhua Pharmaceutical Gains Approval for Eszolam Tablets License Transfer
Apr 14, 2025

Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the change of marketing license holder for its Eszolam tablets. This approval follows a contract signed with Guangxi Dahai Sunshine Pharmaceutical Company Limited for the transfer of the Marketing Authorization Holder status and related technical ownership rights, marking a significant step in the company’s strategic operations.

Shandong Xinhua Pharmaceutical Releases 2024 Financial Results
Mar 28, 2025

Shandong Xinhua Pharmaceutical Company Limited has announced its audited consolidated financial results for the year ending December 31, 2024. The results, prepared in accordance with China Accounting Standards for Business Enterprises, reflect the company’s ongoing commitment to transparency and adherence to regulatory standards, potentially impacting its market positioning and stakeholder confidence.

Shandong Xinhua Pharmaceutical Proposes Amendments to Articles of Association
Mar 28, 2025

Shandong Xinhua Pharmaceutical Company Limited has announced proposed amendments to its Articles of Association following an increase in its issued share capital due to the exercise of options under its Share Option Scheme. Additionally, the company has absorbed Ronghua (Zibo) Property Services Co., Ltd., expanding its business scope to include property management and real estate rental services. These changes necessitate revisions to the company’s Articles of Association, which will be subject to shareholder approval at a general meeting.

Shandong Xinhua Pharmaceutical Declares Final Dividend for 2024
Mar 28, 2025

Shandong Xinhua Pharmaceutical Company Limited has announced a final cash dividend of RMB 0.25 per share for the financial year ending December 31, 2024. The announcement reflects the company’s financial performance and commitment to returning value to shareholders, although specific details regarding the payment date and withholding tax are yet to be disclosed.

Shandong Xinhua Pharmaceutical Schedules Board Meeting for Annual Results
Mar 14, 2025

Shandong Xinhua Pharmaceutical Company Limited has announced that its board of directors will hold a meeting on March 28, 2025, to consider and approve the audited annual results for the year ending December 31, 2024. The meeting will also discuss the recommendation of a final dividend and address any other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.

Shandong Xinhua Pharmaceutical Secures Drug Registration for Pentazocine Injection
Mar 11, 2025

Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Drug Registration Certificate for its Pentazocine injection from the National Medical Products Administration. This approval marks a significant step for the company, allowing it to proceed with the production and sale of the drug, thereby potentially enhancing its market position in the pharmaceutical industry.

Xinhua Pharmaceutical Gains Approval for Clopidogrel Tablets Marketing Transfer
Mar 3, 2025

Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the supplementary application concerning the transfer of marketing authorization holder of Clopidogrel Hydrogen Sulfate Tablets. This approval follows a technology transfer agreement with Beijing Sihuan Pharmaceutical Company Limited, allowing Xinhua Pharmaceutical to acquire the marketing and sales license, along with related rights and interests, for the product. This strategic move is expected to enhance Xinhua Pharmaceutical’s market position and expand its product offerings in the pharmaceutical sector.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.